ID   OVCAR3-533533-R6
AC   CVCL_DH40
SY   533533-R6
DR   cancercelllines; CVCL_DH40
DR   GEO; GSM1186820
DR   GEO; GSM1186825
DR   GEO; GSM1186831
DR   Progenetix; CVCL_DH40
DR   Wikidata; Q54937021
RX   PubMed=24004674;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:132239; PHA-533533.
CC   Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; c.1746-2A>T; Zygosity=Heterozygous; Note=Splice acceptor mutation (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
DI   NCIt; C105555; High grade ovarian serous adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0465 ! OVCAR-3
SX   Female
AG   60Y
CA   Cancer cell line
DT   Created: 13-07-16; Last updated: 05-10-23; Version: 12
//
RX   PubMed=24004674; DOI=10.1158/1078-0432.CCR-13-1337;
RA   Etemadmoghadam D., Au-Yeung G., Wall M., Mitchell C., Kansara M.,
RA   Loehrer E., Batzios C., George J., Ftouni S., Weir B.A., Carter S.,
RA   Gresshoff I., Mileshkin L., Rischin D., Hahn W.C., Waring P.M.,
RA   Getz G., Cullinane C., Campbell L.J., Bowtell D.D.L.;
RT   "Resistance to CDK2 inhibitors is associated with selection of
RT   polyploid cells in CCNE1-amplified ovarian cancer.";
RL   Clin. Cancer Res. 19:5960-5971(2013).
//